Biotech Stock Review

Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.

Added to Watch List November 2019 @$0.55. Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...

The FDA Cracks Down On Stem Cell Therapy.

Due to a somewhat unexpected crackdown on stem cell treatment centers a couple of weeks ago - we have decided to hold...
Issam Radd

Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).

Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR) Summary
Biotech Stock Review. Citius, CTXR

More Great News From Citius Pharma (CTXR).

UPDATED CHART 6-15-21 Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News
Internet Stock Review

Stocks On The Move!

Citius (CTXR) up 19%, Draganfly (DFLYF) up 31%, urban-gro (UGRO) up 37%, Provention (PVRB) flip-flopping, Hapbee Technologies (HAPBF) up 26% and the...
Dalarada, Internet Stock Review

Discontinuing Coverage on Dalrada (DFCO).

We Are Temporarily Discontinuing Coverage on Dalrada Financial. Great little company and we're up 400%. But with the market...

Citius Pharma (CTXR) Updates Shareholders.

Citius Update Stem Cell Study Citius Pharmaceuticals, Inc announced that it will present a poster at the International Society...
Stem Cell Stock Review

Old News, But Wow: Starr Foundation Reaffirms Support for Stem Cell Research with $50...

Someone is a Big Believer and Cutting Equally Big Checks! NEW YORK (April 4, 2019) — The Starr...

Stem Cell Play Organicell (BPSR) Screams Higher.

Stock Levitates After Series of Positive Press Releases on Zofrin. Added to the Watch List in April a...
Citius, Leonard Mazur

Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.

https://youtu.be/vMIy8xWLOKI?t=3699 Starts at 1 Hour Mark. INSIDER HOLDINGS

Latest article

IA Initiates Analyst Coverage of Principal Solar (Press Release).

Principal Solar, Inc.Mon, March 20, 2023 at 7:30 AM EDT Institutional Analyst, Inc....

Selling ARK (ARKK) & Buying AXS Short Innovation (SARK) ETF.

Going Short the Market. No Long Dissertation, No Rush. Market Risk Has Appeared, With Minimal Upside, So Time To Act.

We’re Bearish, but we’re up 257% in Provention Bio (PRVB) Today.

And up 416%, from Adding it to 2022 Watch List! Great way to wake up after a night of...